Product Description
Nafarelin Pharmaceutical API Polypeptide made in china 76932-56-4
AI Product Description
*The following content is generated by AI and is for reference only.
Nafarelin is a potent synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), specifically designed to modulate the hypothalamic-pituitary-gonadal axis. Manufactured in China by leading pharmaceutical API suppliers, this high-purity polypeptide serves as a critical active pharmaceutical ingredient for treating conditions such as endometriosis, central precocious puberty, and prostate cancer. Its molecular formula is C58H79N19O13S2, with a precise molecular weight of approximately 1,246.4 g/mol. The compound features a specific substitution at the sixth position where L-histidine is replaced by D-naphthylalanine, enhancing its stability and receptor affinity compared to natural GnRH.
The CAS number for Nafarelin is 67558-46-9. As a GnRH agonist, it functions through a unique mechanism: initial administration triggers a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, followed by a profound downregulation and desensitization of pituitary GnRH receptors. This leads to a sustained suppression of sex steroid production, effectively creating a reversible medical menopause in women or reducing testosterone levels in men. In clinical settings, it is predominantly formulated as an intranasal spray, allowing for convenient daily dosing directly into the nasal cavity, which ensures rapid absorption and bioavailability.
Beyond its primary therapeutic applications, Nafarelin is extensively utilized in reproductive medicine for controlled ovarian stimulation protocols and assisted reproductive technologies. Chinese manufacturers adhere to strict Good Manufacturing Practice (GMP) standards, ensuring the product meets international quality benchmarks regarding purity, potency, and sterility. The synthesis involves solid-phase peptide chemistry, yielding a highly consistent API suitable for global pharmaceutical markets. With its established safety profile and efficacy, Nafarelin remains a cornerstone therapy for hormone-dependent disorders, offering significant improvements in patient quality of life while minimizing invasive treatments. Its widespread availability from Chinese sources supports the growing global demand for cost-effective, high-quality hormonal therapies.